This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Multiple Myeloma Diagnostics Market

Multiple Myeloma Diagnostics Market By Drug Type (Proteasome, Velcade, Kyprolis, Ninlaro, Immunomodulatory Agents, Thalomid, Revlimid, Pomalyst, Histone Deacetylase, Farydak, Immunotherapy, Darzalex Empliciti Cytotoxic Chemotherapy, Doxil) & Region - Forecast 2022-2032

Market Insights on Multiple Myeloma Diagnostics covering sales outlook, demand forecast & up-to-date key trends

Multiple Myeloma Diagnostics Market Overview

Multiple myeloma diagnostics market is likely to record a promising CAGR 10.3% during the forecast period. The market is currently valued at US$ 13.62 Bn and is likely to reach US$ 32.91 Bn by 2032.

Attributes

Details

Multiple Myeloma Diagnostics Market CAGR (2022-2032)

10.3%

Multiple Myeloma Diagnostics Market Value (2022)

US$ 13.62 Bn

Multiple Myeloma Diagnostics Market Value (2032)

US$ 32.91 Bn

Multiple plasma cells help in fighting various infections, but malignant plasma cells accumulate in bone marrow restricts the basic functionality of a plasma cell. The “M” or the antibody protein extracted from malignant plasma cells causes bone destruction, tumor, kidney damage and restricts immune functions. As these types of diseases increase in number day by day, there is a push in demand for multiple myeloma diagnostics.

Awareness about health and the increasing number of patients suffering from cancer and other chronic diseases are also pushing the sales of multiple myeloma diagnostics systems. Also, increased funding from governments for the setup of these diagnostics centers is hyping up the demand for multiple myeloma diagnostics.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Key Drivers and Restraints to the Multiple myeloma diagnostics Market?

Plasma cells help in fighting infection; however, malignant plasma cells in multiple myeloma accumulate in the bone marrow, which blocks the normal function of plasma cells. The M protein, which is an abnormal antibody produced by malignant plasma cells, causes tumors, bone destruction, kidney damage, and damaged immune function.

However, in recent years, ten new drugs have received approval in a short period of time due to the formation of the Multiple Myeloma Research Foundation and the increasing attention, advancement, and research for multiple myeloma diagnostics and therapies. These factors help in increasing the demand for multiple myeloma diagnostics.

These factors contribute to the growth of the multiple myeloma diagnostics market. Moreover, increasing funding for the research and development and rising clinical trials is expected to provide the most promising multiple myeloma treatments options and will boost the growth of the multiple myeloma diagnostics market.

Technological advancement and rising clinical studies for the management of multiple myeloma are the main factors to boost the market growth of the multiple myeloma diagnostics market.

Additionally, rising disposable income is expected to boost the growth of the multiple myeloma diagnostics market. However, lack of awareness and expertise can lead to complications and can damage the immune function of the heart, which may lead to heart failure. The poor management of multiple myeloma may lead to restraint the growth of the multiple myeloma diagnostics market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Region holds the Prominence in Multiple Myeloma Diagnostics Market?

The Asia Pacific multiple myeloma diagnostics market is expected to show fast growth due to rising heart-related problems and a lack of awareness regarding the management of multiple myeloma.

The multiple myeloma diagnostics market is expected to be dominated by North America due to advanced healthcare infrastructure and reimbursement in the region.

Latin America Multiple myeloma diagnostics market is expected to experience steady growth due to a lack of expertise in the region. Europe is expected to score second place in the multiple myeloma diagnostics market due to the availability of skilled healthcare professionals coupled with higher adoption in the region.

The Middle East & Africa is expected to be the least lucrative multiple myeloma diagnostics market due to the least product availability and lack of facilities in the region.

How’s the Competitive Landscape in Multiple Myeloma Diagnostics Market?

The key players of the multiple myeloma diagnostics market are focusing on enhancing and adopting strategies like mergers, approvals, upgrades and extending centers to drive the demand for multiple myeloma diagnostics business. This is driving the sales of Multiple myeloma diagnostics. 

Key players in multiple myeloma diagnostics market include Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, Thermo Fisher Scientific Inc, Celgene Corporation, Millennium Pharmaceuticals, Norvartis AG, Amgen Inc, Juno Therapeutics, Janssen Biotech Inc, Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc, Onyx Pharmaceuticals, Celldex Theapeutics Inc and Innate Pharma SA.

Recent Market Development:

  • Janssen Pharmaceuticals of Johnson and Johnson has introduced CARVYKTI that is also approved by US Food and Drug Administration for the treatment of multiple myeloma, increasing the sales of multiple myeloma diagnostics system.
  • Thermo Fisher Scientific has received a manufacturer leader innovation award, winning the trust of end users and enhancing the demand for multiple myeloma diagnostics systems.
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope of Report

Report Attribute

Details

Growth Rate

CAGR of 10.3% from 2022 to 2032

Base year for estimation

2021

Historical data

2015 - 2020

Forecast period

2022 - 2032

Quantitative units

Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032

Report coverage

Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,

Segments covered

Drug Type, Distribution Channel, Region

Regional scope

North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand

Country scope

U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa

Key companies profiled

Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, Celgene Corporation, Millennium Pharmaceuticals, Norvartis AG, Amgen Inc, Juno Therapeutics, Janssen Biotech Inc, Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc, Onyx Pharmaceuticals, Celldex Theapeutics Inc and Innate Pharma SA,

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. 

Frequently Asked Questions

Institutional sales is the biggest segment in the multiple myeloma diagnostics market by distribution channel and is expected to hold a big portion of the market in the forecast period. The leading factor is the easy availability due to strong supply chain. This leads to the high demand for Multiple myeloma diagnostics in developing countries.

Key competitors holding substantial multiple myeloma diagnostics market share are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Genzyme Corporation, Celgene Corporation, Millennium Pharmaceuticals, Norvartis AG, Amgen Inc, Juno Therapeutics, Janssen Biotech Inc, Johnson & Johnson, GlaxoSmithKline plc, Pfizer, AbbVie Inc, Onyx Pharmaceuticals, Celldex Theapeutics Inc and Innate Pharma SA,

Demand for Multiple myeloma diagnostics is likely to rise with increasing number of patients that suffer from disease generated by malignant cells, increasing awareness and inactive lifestyle leading up to new diseases, increasing the sales of multiple myeloma diagnostics.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Multiple Myeloma Diagnostics Market